Analysis of Incidence and Risk Factors for Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.32429/JKSHP.2014.31.3.003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic variation associated with bortezomib-induced peripheral neuropathy

  2011cited by this paper
• Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.

  2010cited by this paper
• Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

  2010cited by this paper
• Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

  2010cited by this paper
• Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

  2009cited by this paper
• Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

  2009cited by this paper
• Identification of a Diagnostic Gene Signature for SGN-40, Anti-CD40 Monoclonal Antibody, in Pre-Clinical NHL Models and the Role of FAS in SGN-40 Mediated Apoptosis.

  2008cited by this paper
• Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

  2008cited by this paper
• Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?

  2008cited by this paper
• Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.

  2008cited by this paper
• Review of peripheral neuropathy in plasma cell disorders

  2008cited by this paper
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008cited by this paper
• Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma

  2007cited by this paper
• Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature

  2007cited by this paper
• Quantitative sensory findings in patients with bortezomib-induced pain.

  2007cited by this paper
• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

  2006cited by this paper
• A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer.

  2006cited by this paper
• A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma

  2006cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy

  2003cited by this paper

• No citing papers are available for this paper.